4d Pharma Share Discussion Threads

[jackrussell3] 27/2/2021 07:15

Very confident once we reach US shores we’ll get a fairer hearing. AIM is no place for a innovative & potentially life saving bioscience company. Nasdaq is chance for a fresh start - away from toxic cuck U.K. investors - & will breathe new life into this stock. Can’t wait for 4D to introduce themselves to US OF A.

[freddie ferret] 26/2/2021 22:29

That must be because there are some people out there that are keen to short it.

[tyler90] 26/2/2021 19:58

4d Pharma escaped the cull

[devonlad] 26/2/2021 19:51

Strange, I didn't get a margin call from it!

[thepaddedcell] 26/2/2021 17:30

We started the month at 110p or so, we have been nudging 150p on more than one occasion. The trend is an upward one, no doubt about it !

[tyler90] 26/2/2021 17:17

Yeah! finished at 136 which was the price just after 3pm

[eeza] 26/2/2021 17:08

1500hrs today was the IG deadline to cover margin at 100%. Positions were closed at 1500, where the extra margin was not posted.

[tyler90] 26/2/2021 16:59

IG margin calls played a part in the fall Folk selling profitable positions to cover the margin call is my guess

[eeza] 26/2/2021 16:41

Stig
'the 1st hour is retail'

The 'smart' money, in the last hour, just took the share price to the day's low at the close.

[freddie ferret] 26/2/2021 15:45

Feel sorry for you today, it should have been a good day here, however it looks like US markets tanking. :))

[katsy] 26/2/2021 15:44

Err stig we've been over this, it got within 8p of my buy order, a lot closer than your £10 prediction. Anyway yes macro conditions are important. Just look at the sea of red out there.

[katsy] 26/2/2021 15:24

Market sell-off so not really specific to 4D. FED losing control US bond yields

[slartybartfaster] 26/2/2021 15:22

Only cheerleaders allowed here.

[mealiff] 26/2/2021 15:20

that old saying ,"Sell on news " could be haunting the price today

[eeza] 26/2/2021 15:18

The Stigologist26 Feb '21 - 08:56 - 18421 of 18452
0 4 0
First hour is retail

[devonlad] 26/2/2021 13:30

Backed by the directors:

As announced by the Company on 22 October 2020, the participation by Duncan Peyton in the Backstop Arrangements in the amount of up to US$1,075,862 and the participation by Alex Stevenson in the Backstop Arrangements in the amount of up to US$827,856, both constitute related party transactions for the purposes of the AIM Rules because, if funds are withdrawn from the Longevity trust account, the Backstop Investors will make up the shortfall so that the US$14.6 million in the trust account at the time the Merger was announced will be available to the Enlarged Group at Completion. As a result of the terms of these Backstop Arrangements, the shareholdings in the Company of Duncan Peyton and Alex Stevenson could increase.

For the same reasons as noted above, the participation by Steve Oliveira and connected parties, a substantial shareholder (as defined by the AIM Rules) in the Company, in the Backstop Arrangements in the amount of up to US$5 million (in aggregate) is also a related party transaction.

[royalalbert] 26/2/2021 13:09

Remember "up to $347.5m in milestone payments per indication".

[thresholdbypass] 26/2/2021 12:59

Sorry, was referring to the fast-track. Funding seems just a way of keeping that option open and in their own hands, will happen of course, but not clear yet when

[thresholdbypass] 26/2/2021 12:57

Yeah Devonlad, certainly something they are working on, would be $$$$ ok if that happened!

[devonlad] 26/2/2021 12:57

REad:

The Board anticipates that additional finance will come primarily from equity funding and expects that additional funds can be raised before Q3 2021. The Board is considering the option of raising a minimum of US$25 million and intends to approach a limited number of qualified institutional buyers and institutional accredited investors regarding a potential private placement of its Ordinary Shares or ADSs. This financing transaction, if completed, could close contemporaneously with, or on a date after, the completion of the Merger. The decision regarding how much to raise or whether to proceed or not, will depend on the prevailing market conditions, investor appetite and price, and there is no certainty that any such fundraising transaction will proceed nor what amount might be raised.

The Board is therefore seeking approval at the General Meeting to issue new shares on a non-pre-emptive basis for up to 40 per cent. of the Company's Enlarged Issued Share Capital (following Completion). The Board will update Shareholders as appropriate regarding any future funding proposals. It remains of the opinion that the NASDAQ Listing will provide access to specialist healthcare investors in the US.

[devonlad] 26/2/2021 12:47

Do you thiunk any of the cucks actually bother to read the rns?

This points to an FDA fast track application imho:

-- continued engagement with the FDA in 2021 to discuss the development and approval pathway for MRx0518 in combination with an ICI in patients with solid tumours and secondary resistance to prior ICI therapy;

[zydecoco] 26/2/2021 12:40

Thank you muddy40, I am aware of those and am hoping to find more which would support LBPS' arrival in USA to the wider and retail market beyond institutional investors.

[muddy_40] 26/2/2021 12:37

They have these events coming up.

As for PR they have hired below US company.